Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 641Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents      
FROM THE WORLD OF CLINICAL RESEARCH
Year : 2012  |  Volume : 3  |  Issue : 4  |  Page : 148

Drug discovery and clinical trials: A poem


Medical Affairs & Safety, Karmic Lifesciences, 802, Bldg 3, Raheja Mindspace, Airoli SEZ, Airoli, Navi Mumbai, India

Date of Web Publication19-Nov-2012

Correspondence Address:
Lakshmi Balachandran
Medical Affairs & Safety, Karmic Lifesciences, 802, Bldg 3, Raheja Mindspace, Airoli SEZ, Airoli, Navi Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.103598

Rights and Permissions

How to cite this article:
Balachandran L. Drug discovery and clinical trials: A poem. Perspect Clin Res 2012;3:148

How to cite this URL:
Balachandran L. Drug discovery and clinical trials: A poem. Perspect Clin Res [serial online] 2012 [cited 2019 Aug 21];3:148. Available from: http://www.picronline.org/text.asp?2012/3/4/148/103598

The human body is indeed a wonder,

Sure, you don't have to look yonder,

When its functions go asunder,

To set it right, scientists and medicos begin to ponder.

The first is the "Target Identification" phase,

Whether the target is Adenyl cyclase or Protein kinase?

At the end of the "Target Validation" phase,

The excited scientist begins work from a new base.

Begins the best drug hunting spree,

In the trees, oceans and the high seas,

They sift the target molecule free,

And decide, 'How to make the world agree?'

First is the chemical identification,

Maceration, decoction yields the "Active" ingredient in isolation,

RP-HPLC separation and Mass-directed fractionation,

Various techniques adopted for extraction and purification.

High potency, selectivity and oral bioavailability,

With little or no interaction with CYP450,

Minimal adverse effects tilt the mandate,

With high Therapeutic Index favoring a drug's fate.

Satisfied, the chemical now goes for TOX studies (Toxicological studies),

And many many cohorts of animal studies,

Some animals survive, some lose their buddies,

Bioavailability, mutagenicity and teratogenicity are some other studies.

Work now progresses to the IND application,

The FDA/DCGI checks ALL the information,

Preclinical study data, protocols and drug source and composition,

Credentials of trial physicians and drug manufacturing information.

And once the permission comes through,

Identifying the best CRO is indeed a breakthrough,

The Clinical trials now take place in a sequence,

With Sponsors, Investigators, EC and Subjects in an alliance.

Phase I assesses safe dosage range and Side effects,

Phase II further assesses "Efficacy" in Patient subjects,

Phase III confirms data from the previous phase,

The NDA application now enters the race.

The Drug regulatory authority after careful reviewing,

Approves or rejects a new drug for marketing,

If approved, the patients have a new treatment in the offing,

Soon the hitherto immortal BUG, would take a good beating.




 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article

 Article Access Statistics
    Viewed980    
    Printed62    
    Emailed0    
    PDF Downloaded293    
    Comments [Add]    

Recommend this journal